EPAS1 and renal cell carcinoma: However, belzutifan could not enhance SKPin C1's effect on VHL-deficient RCC cells (Supplementary Fig. S6C), implying that there could be a varying combination effect of HIF-2α specific inhibitor with different classes of anti-microtubule agents.